drugset / Trial / NCT00741273
Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
Non-randomizedParallel-groupOpen-label
Summary
This study will evaluate the safety and pharmacokinetics of two doses of orally administered Proellex® in female patients with impaired hepatic function and healthy volunteers with normal hepatic function.
Timeline
- Start
- 2008-10
- Primary completion
- 2009-05
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Telapristone Acetate | Other / unclassified | 25 mg | Oral |
| Subject | Telapristone Acetate | Other / unclassified | 50 mg | Oral |